Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C4LF
|
|||
| Former ID |
DNCL002412
|
|||
| Drug Name |
ARRY-162
|
|||
| Synonyms |
606143-89-9; Binimetinib; MEK162; MEK-162; ARRY-438162; 5-[(4-Bromo-2-fluorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide; ARRY 162; UNII-181R97MR71; Binimetinib (MEK162, ARRY-162, ARRY-438162); 181R97MR71; MEK162 (ARRY-162, ARRY-438162); 6-(4-bromo-2-fluorophenylamino)-7-fluoro-N-(2-hydroxyethoxy)-3-methyl-3H-benzo[d]imidazole-5-carboxamide; Binimetinib [USAN:INN]; MEK 162; ARRY 438162; MEK162(Binimetinib); Binimetinib (JAN/USAN); D0C4LF; NVP-ME
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Approved | [1] | |
| Company |
Array BioPharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H15BrF2N4O3
|
|||
| Canonical SMILES |
CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)F)C(=O)NOCCO
|
|||
| InChI |
1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)
|
|||
| InChIKey |
ACWZRVQXLIRSDF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 606143-89-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15294150, 22663761, 35560186, 76385017, 136920431, 139722085, 152256088, 152258645, 160647480, 162011797, 162108908, 163750757, 164042001, 172919200, 174006430, 174529974, 185990487, 198988096, 223386768, 223705205, 225848212, 226876700, 242590736, 243963093, 249565604, 252215762, 252450328, 252554049
|
|||
| ChEBI ID |
CHEBI:145371
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
| REF 2 | MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.